secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001628280-25-005018
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive to present Anaphylm data at AAAAI: symptom resolution in 12 min, stable under extreme conditions
--------------------------------------------------------------------------------

- Median symptom resolution time 12 min vs 74 min without treatment; mean angioedema resolution within 5 min.
- Anaphylm matched or exceeded IM epinephrine in all key PK parameters in Phase 2 OASIS study.
- Stability and potency maintained under extreme heat, freezing, and water submersion.
- Presentations at AAAAI Annual Meeting Feb 28 – Mar 3, 2025 in San Diego.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025005018/0001628280-25-005018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025005018/aqst-20250212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-005018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer